New Drugs for the Treatment of Lymphoma

Keyphrases

• New Drugs 100%
• Chronic Myeloid Leukemia 100%
• Imatinib 100%
• Lymphoma Treatment 100%
• Solid Tumors 50%
• Myeloma 50%
• B-cell Lymphoma 2 (Bcl-2) 50%
• Lymphoma 50%
• Drug Development 50%
• New Targets 50%
• CD40 50%
• Hematological Malignancies 50%
• Innovative Drugs 50%
• Genetic Lesions 50%
• Mammalian Target of Rapamycin Signaling Pathway 50%
• Blood Cancer 50%
• Biochemical Pharmacology 50%
• Phosphoinositide 3-kinase/Akt 50%
• Leukemia/Lymphoma 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Myeloid Leukemia 100%
• Imatinib 100%
• Drug Development 50%
• Protein Kinase B 50%
• Leukemia 50%
• Phosphatidylinositol 3 Kinase 50%
• Solid Malignant Neoplasm 50%
• Myeloma 50%
• Hematologic Malignancy 50%
• Mammalian Target of Rapamycin 50%
• Biochemical Pharmacology 50%

Medicine and Dentistry

• Chronic Myelogenous Leukemia 100%
• Imatinib 100%
• Solid Malignant Neoplasm 50%
• Myeloma 50%
• Protein Kinase B 50%
• Leukemia 50%
• Hematologic Malignancy 50%
• Mechanistic Target of Rapamycin 50%
• Phosphoinositide 3-Kinase 50%
• Hematological Cancer 50%
• Genetics 50%